Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cialis NDA Issues Include Back Pain At 20 Mg Dose, FDA Documents Show

Executive Summary

FDA's safety questions about Lilly/Icos' erectile dysfunction agent Cialis focus on back pain reported at the starting dose initially proposed by the companies

You may also be interested in...



UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004

UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004

UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004

UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004

Bayer Repinotan Development Slowed By Dosing Issue, FDA Documents Show

Bayer will use a loading dose of the stroke drug repinotan in Phase III trials following discussions with FDA over how best to maximize treatment response, agency documents show

Related Content

UsernamePublicRestriction

Register

PS042824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel